Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Expenditure for Senshin-Iryo Services Totaled 17.4 Billion Yen: MHLW
January 29, 2015
- Chuikyo Approves Insurance Reimbursement for Companion Diagnostic for Zelboraf
January 29, 2015
- Government Releases Strategy for Dementia
January 28, 2015
- Prof. Hashida of Kyoto University Elected as PAFSC Chairman
January 28, 2015
- Panel OKs Requirements to Give Legal Status to Clinical Research Core Hospitals
January 27, 2015
- Panel on Unapproved Drugs Weighs Revamp upon Rollout of New Development Request Scheme
January 27, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 12 - 25
January 26, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- Council OKs Application Based on Info in Public Domain for Taxol Once Weekly for 3 Weeks for Gastric Cancer
January 26, 2015
- PMDA Evaluating Apixaban for Risk of Interstitial Pneumonia
January 26, 2015
- Government Launches Genomic Medicine Panel
January 23, 2015
- Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
- NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger
January 22, 2015
- NIBIO Completes Development of Prototype Adjuvant Database
January 22, 2015
- PAFSC’s Second Committee on Drugs Recommends Approval for Eisai’s Lenvatinib
January 22, 2015
- R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
- Health Ministry Reveals Guidelines on Research Misconduct
January 20, 2015
- R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
- Consumer Affairs Agency to Begin Study on Child-Resistant PTP Sheets
January 20, 2015
- PAFSC 1st Committee to Discuss Takeda’s Once-Weekly DPP-4 Inhibitor on Jan. 30
January 20, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…